Back to Search Start Over

Heat-treated and/or lysozyme-treated Enterococcus faecalis (FK-23) improves the progression of renal disease in a unilateral ischemia-reperfusion injury rat model.

Authors :
Takemura S
Minamiyama Y
Ito N
Yamamoto A
Ichikawa H
Nakagawa K
Toyokuni S
Osada-Oka M
Yoshikawa T
Source :
Journal of clinical biochemistry and nutrition [J Clin Biochem Nutr] 2024 Jul; Vol. 75 (1), pp. 78-89. Date of Electronic Publication: 2024 Apr 04.
Publication Year :
2024

Abstract

The prevalence of chronic kidney disease (CKD) is increasing owing to the elderly population. Here, we investigated the effects of heat-treated Enterococcus faecalis (FK-23) and lysozyme-treated FK-23 (LFK) on the progression of CKD in rats. A CKD model was established using male Wistar rats by subjecting them to right nephrectomy (1K), followed by ischemia and reperfusion (IR). FK-23 or LFK was fed ad libitum as a mixed diet after right nephrectomy. Animals subjected to renal ischemia-reperfusion injury (IRI) showed increased plasma creatinine and blood urea nitrogen levels. Furthermore, in the kidneys, collagen accumulation and α-smooth muscle actin, indicative of fibroblast activation and fibrosis-related gene and protein expression, increased 3 weeks after IRI. FK-23 and LFK suppressed the increase in the mRNA levels of some of these genes. The increase in oxidative stress markers, 4-hydroxy-2-nonenal, endothelial nitric oxide synthase, and nitrotyrosine in the kidney, as well as increased plasma uremic toxins after IRI, were also ameliorated by FK-23 and LFK. Metagenomic analysis of fecal samples revealed that gut microbial alteration caused by IRI was also ameliorated by LFK treatment. These results suggest that Enterococcus faecalis ingredients may improve CKD progression by suppressing oxidative stress and correcting the balance of the intestinal microflora.<br />Competing Interests: ST, YM, and TY received an unrestricted grant from Nichinichi Pharmaceutical Co., Ltd. (Mie, Japan). NI is supported by Nichinichi Pharmaceutical Co., Ltd. as an outside work in this study. The funders had no role in the data analysis and interpretation. KN is employed by Nichinichi Pharmaceutical Co., Ltd. The remaining authors declare no competing interests.<br /> (Copyright © 2024 JCBN.)

Details

Language :
English
ISSN :
0912-0009
Volume :
75
Issue :
1
Database :
MEDLINE
Journal :
Journal of clinical biochemistry and nutrition
Publication Type :
Academic Journal
Accession number :
39070538
Full Text :
https://doi.org/10.3164/jcbn.24-29